Literature DB >> 25529097

HBV and the immune response.

Carlo Ferrari1.   

Abstract

Hepatitis B virus (HBV) infection acquired in adult life is generally self-limited while chronic persistence of the virus is the prevalent outcome when infection is acquired perinatally. Both control of infection and liver cell injury are strictly dependent upon protective immune responses, because hepatocyte damage is the price that the host must pay to get rid of intracellular virus. Resolution of acute hepatitis B is associated with functionally efficient, multispecific antiviral T-cell responses which are preceded by a poor induction of intracellular innate responses at the early stages of infection. Persistent control of infection is provided by long-lasting protective memory, which is probably sustained by continuous stimulation of the immune system by trace amounts of virus which are never totally eliminated, persisting in an occult episomic form in the nucleus of liver cells even after recovery from acute infection. Chronic virus persistence is instead characterized by a lack of protective T-cell memory maturation and by an exhaustion of HBV-specific T-cell responses. Persistent exposure of T cells to high antigen loads is a key determinant of functional T-cell impairment but also other mechanisms can contribute to T-cell inhibition, including the tolerogenic effect of the liver environment. The degree of T-cell impairment is variable and its severity is related to the level of virus replication and antigen load. The antiviral T-cell function is more efficient in patients who can control infection either partially, such as inactive HBsAg carriers with low levels of virus replication, or completely, such as patients who achieve HBsAg loss either spontaneously or after antiviral therapy. Thus, understanding the features of the immune responses associated with control of infection is needed for the successful design of novel immune modulatory therapies based on the reconstitution of efficient antiviral responses in chronic HBV patients.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Immune modulatory therapies; Innate responses; T cell exhaustion; T cell memory; T cells

Mesh:

Substances:

Year:  2015        PMID: 25529097     DOI: 10.1111/liv.12749

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  58 in total

1.  Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.

Authors:  Lu Wang; Yijin Wang; Shuhong Liu; Xiangwei Zhai; Guangde Zhou; Fengmin Lu; Jingmin Zhao
Journal:  J Gastroenterol       Date:  2019-05-27       Impact factor: 7.527

2.  Superinfective Hepatitis E Virus Infection Aggravates Hepatocytes Injury in Chronic Hepatitis B.

Authors:  Semvua Bukheti Kilonzo; Yong-Li Wang; Qun-Qun Jiang; Wen-Yu Wu; Peng Wang; Qin Ning; Mei-Fang Han
Journal:  Curr Med Sci       Date:  2019-10-14

Review 3.  Genome editing and the next generation of antiviral therapy.

Authors:  Daniel Stone; Nixon Niyonzima; Keith R Jerome
Journal:  Hum Genet       Date:  2016-06-08       Impact factor: 4.132

4.  Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection.

Authors:  S B Troy; A E B Rossheim; J Siik; T D Cunningham; J A Kerry
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

5.  iNKT cells in chronic HBV: a balancing act.

Authors:  Maike Hofmann; Robert Thimme
Journal:  Hepatol Int       Date:  2016-05-24       Impact factor: 6.047

6.  Interaction between Toll-Like Receptor 9-CpG Oligodeoxynucleotides and Hepatitis B Virus Virions Leads to Entry Inhibition in Hepatocytes and Reduction of Alpha Interferon Production by Plasmacytoid Dendritic Cells.

Authors:  Ludovic Aillot; Marc Bonnin; Malika Ait-Goughoulte; Nathalie Bendriss-Vermare; Sarah Maadadi; Laura Dimier; Miroslava Subic; Caroline Scholtes; Isabel Najera; Fabien Zoulim; Julie Lucifora; David Durantel
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 7.  Host-virus interactions in hepatitis B virus infection.

Authors:  Luca G Guidotti; Masanori Isogawa; Francis V Chisari
Journal:  Curr Opin Immunol       Date:  2015-07-15       Impact factor: 7.486

8.  CD45RO+ T Cells and T Cell Activation in the Long-Lasting Immunity after Leishmania infantum Infection.

Authors:  João F Rodrigues-Neto; Gloria R Monteiro; Tatjana S L Keesen; Henio G Lacerda; Edgar M Carvalho; Selma M B Jeronimo
Journal:  Am J Trop Med Hyg       Date:  2017-12-21       Impact factor: 2.345

9.  The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

Authors:  Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Benjamin Fram; Jeffrey S Glenn; David E Kleiner; Christopher Koh; Theo Heller
Journal:  J Gastroenterol Hepatol       Date:  2019-02-25       Impact factor: 4.029

Review 10.  [Chronic hepatitis B and D (delta) : Current and future treatments].

Authors:  N Wortmann; C Höner Zu Siederdissen; M Cornberg
Journal:  Internist (Berl)       Date:  2018-06       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.